Follow The Filings

Avidity Partners Management LP David Witzke

Dallas, TX 21 processed 13Fs on this site, 2021 Q3 to 2026 Q2

  • $624M
  • 45 holdings
  • 2026 Q2
  • +41.2% QoQ
  • Top 5 70.9%

Portfolio

2026 Q2, filed 8/14/2026, top 12 of 45 holdings

Top 5 70.9%, top 10 81.9%

  1. DNTH, Dianthus Therapeutics 32.8%
  2. CGON, CG Oncology 15.9%
  3. ORKA, Oruka Therapeutics 11.6%
  4. JBIO, Jade Biosciences 6.1%
  5. ELVN, Enliven Therapeutics 4.5%
  6. CATX, Perspective Therapeutics 3.4%
  7. AKTS, Aktis Oncology 2.5%
  8. PVLA 1.7%
  9. MOBI, Mobia Medical 1.7%
  10. RGEN, Repligen 1.7%
  11. Immunic 1.6%
  12. Senseonics 1.5%
  13. Other 15.0%

AUM over time

2026 Q2 $624M +41.2% QoQ
2021 Q3: $4.5B 2021 Q3: $4.5B
Q3 2021
2021 Q4: $4.7B, +4.5% QoQ 2021 Q4: $4.7B, +4.5% QoQ
Q4
2022 Q1: $4.8B, +1.9% QoQ 2022 Q1: $4.8B, +1.9% QoQ
Q1 2022
2022 Q2: $4.4B, −9.3% QoQ 2022 Q2: $4.4B, −9.3% QoQ
Q2
2022 Q3: $4.9B, +12.9% QoQ 2022 Q3: $4.9B, +12.9% QoQ
Q3
2022 Q4: $4.6B, −6.2% QoQ 2022 Q4: $4.6B, −6.2% QoQ
Q4
2023 Q1: $3B, −34.7% QoQ 2023 Q1: $3B, −34.7% QoQ
Q1 2023
2023 Q2: $2.9B, −5.0% QoQ 2023 Q2: $2.9B, −5.0% QoQ
Q2
2023 Q3: $2.5B, −13.3% QoQ 2023 Q3: $2.5B, −13.3% QoQ
Q3
2023 Q4: $2.7B, +10.5% QoQ 2023 Q4: $2.7B, +10.5% QoQ
Q4
2024 Q1: $3.1B, +13.0% QoQ 2024 Q1: $3.1B, +13.0% QoQ
Q1 2024
2024 Q2: $2.4B, −24.1% QoQ 2024 Q2: $2.4B, −24.1% QoQ
Q2
2024 Q3: $2B, −16.7% QoQ 2024 Q3: $2B, −16.7% QoQ
Q3
2024 Q4: $1B, −48.1% QoQ 2024 Q4: $1B, −48.1% QoQ
Q4
2025 Q1: $525M, −48.4% QoQ 2025 Q1: $525M, −48.4% QoQ
Q1 2025
2025 Q2: $502M, −4.4% QoQ 2025 Q2: $502M, −4.4% QoQ
Q2
2025 Q3: $439M, −12.5% QoQ 2025 Q3: $439M, −12.5% QoQ
Q3
2025 Q4: $347M, −21.0% QoQ 2025 Q4: $347M, −21.0% QoQ
Q4
2026 Q1: $442M, +27.4% QoQ 2026 Q1: $442M, +27.4% QoQ
Q1 2026
2026 Q2: $624M, +41.2% QoQ 2026 Q2: $624M, +41.2% QoQ
Q2

Book

2025 Q2 2025 Q1, filed 14 Aug, long equity only

Download CSV Download Excel All activity
CGON, CG Oncology 7.77%, was 4.58% Add +52.9% 1,499,942 $26.00 $39M +519,000 +$15M
BSX, Boston Scientific 6.89% Reduce −4.2% 321,800 $107.41 $35M −14,200 +$669K
NTRA, Natera 6.71%, was 3.21% Add +67.2% 199,300 $168.94 $34M +80,100 +$17M
DNTH, Dianthus Therapeutics 6.47%, was 5.95% Add +1.3% 1,742,902 $18.63 $32M +22,000 +$1.3M
Exact Sciences 3.76%, was 2.91% Add +0.6% 355,000 $53.14 $19M +2,000 +$3.6M
THC, Tenet Healthcare 3.72%, was 1.85% Add +47.2% 106,000 $176.00 $19M +34,000 +$9M
DXCM, DexCom 3.66%, was 2.34% Add +16.9% 210,500 $87.29 $18M +30,500 +$6.1M
DHR, Danaher 3.53%, was 1.74% Add +101.6% 89,700 $197.54 $18M +45,200 +$8.6M
HNGE 3.32% New 322,344 $51.75 $17M +322,344 +$17M
INTU, Intuitive Surgival 2.93% New 27,100 $543.41 $15M +27,100 +$15M
GMAB, Genmab A/s 2.68% New 650,000 $20.66 $13M +650,000 +$13M
RGEN, Repligen 2.64% New 106,500 $124.38 $13M +106,500 +$13M
TMO, Thermo Fisher Scientific 2.39%, was 1.47% Add +91.0% 29,600 $405.46 $12M +14,100 +$4.3M
TEVA, Teva Pharmaceutical Industries 2.30%, was 1.41% Add +43.3% 689,500 $16.76 $12M +208,500 +$4.2M
JBIO, Jade Biosciences 2.24% New 1,127,186 $9.99 $11M +1,127,186 +$11M
PHAT, Phathom Pharmaceuticals 2.03%, was 0.96% Add +33.1% 1,064,500 $9.59 $10M +264,500 +$5.2M
UNH, UnitedHealth Group 1.99%, was 5.04% Reduce −36.6% 32,000 $311.97 $10M −18,500 −$16M
MCK, McKesson 1.97% New 13,500 $732.78 $9.9M +13,500 +$9.9M
AXSM, Axsome Therapeutics 1.97%, was 1.71% Add +22.7% 94,500 $104.39 $9.9M +17,500 +$884K
COR, Cencora 1.96%, was 2.08% Reduce −16.5% 32,800 $299.85 $9.8M −6,500 −$1.1M
HQY, Healthequity 1.92%, was 1.31% Add +17.9% 92,000 $104.76 $9.6M +14,000 +$2.7M
EHC, Encompass Health 1.81% New 74,000 $122.63 $9.1M +74,000 +$9.1M
RVMD, Revolution Medicines 1.68%, was 1.44% Add +7.3% 228,600 $36.79 $8.4M +15,600 +$879K
Akero Therapeutics 1.42%, was 0.44% Add +135.1% 134,000 $53.36 $7.2M +77,000 +$4.8M
Omada Health 1.42% New 390,600 $18.30 $7.1M +390,600 +$7.1M
BEAM, Beam Therapeutics 1.39%, was 2.64% Reduce −42.3% 409,400 $17.01 $7M −300,117 −$6.9M
HUM, Humana 1.34%, was 4.08% Reduce −65.9% 27,600 $244.48 $6.7M −53,400 −$15M
CATX, Perspective Therapeutics 1.27% Reduce −15.4% 1,858,596 $3.44 $6.4M −338,674 +$1.7M
OGN, Organon 1.23% Add +19.6% 640,000 $9.68 $6.2M +105,000 −$1.8M
BBIO, Bridgebio 1.20%, was 0.49% Add +86.7% 140,000 $43.18 $6M +65,000 +$3.5M
INSM, Insmed 1.18%, was 1.56% Reduce −44.9% 59,000 $100.64 $5.9M −48,000 −$2.2M
MDGL, Madrigal Pharmaceuticals 1.15% New 19,000 $302.64 $5.8M +19,000 +$5.8M
RARE 1.12%, was 2.22% Reduce −52.2% 154,000 $36.36 $5.6M −168,100 −$6.1M
CNTX, Context Therapeutics 0.98%, was 0.87% Add 0.0% 7,477,255 $0.6552 $4.9M +55 +$323K
ORKA, Oruka Therapeutics 0.79% Hold 352,124 $11.21 $3.9M — —
IMUX, Immunic 0.78% Add +26.1% 5,615,811 $0.6975 $3.9M +1,161,403 −$938K
ARQT, Arcutis Biotherapeutics 0.75% New 268,000 $14.02 $3.8M +268,000 +$3.8M
DOCS, Doximity 0.73%, was 1.35% Reduce −51.0% 60,000 $61.34 $3.7M −62,500 −$3.4M
XENE, Xenon Pharmaceuticals 0.67%, was 1.46% Reduce −52.9% 107,891 $31.30 $3.4M −121,109 −$4.3M
Holding 0.64% New 33,800 $94.58 $3.2M +33,800 +$3.2M
QURE, Uniqure 0.57%, was 0.68% Reduce −38.4% 207,000 $13.94 $2.9M −129,200 −$678K
APGE, Apogee Therapeutics 0.56% New 65,000 $43.43 $2.8M +65,000 +$2.8M
SLNO, Soleno Therapeutics 0.53% Hold 32,000 $83.78 $2.7M — —
CAH, Cardinal Health 0.50% New 15,000 $168.00 $2.5M +15,000 +$2.5M
SPRY, Ars Pharmaceuticals 0.49% New 140,000 $17.45 $2.4M +140,000 +$2.4M
Kezar Life Sciences 0.46% Hold 502,600 $4.58 $2.3M — —
INTC, Intellia Therapeutics 0.43% New 232,000 $9.38 $2.2M +232,000 +$2.2M
MLTX, Moonlake Immunotherapeutics 0.37% New 39,000 $47.20 $1.8M +39,000 +$1.8M
ARVN, Arvinas 0.36%, was 0.55% Reduce −41.1% 243,162 $7.36 $1.8M −170,000 −$1.1M
SNDX, Syndax Pharmaceuticals 0.28%, was 2.17% Reduce −83.8% 150,000 $9.36 $1.4M −775,000 −$10M

Showing top 50 of 55 by value

Exits / last held

Gone since 2025 Q1, shown at their last reported size.

Stock % of portfolio Recent activity Shares Reported price* Value Share change $ change
REGN, Regeneron 3.07% Exit 0 $634.21 $16M −25,400 −$16M
GKOS, Glaukos 2.51% Exit 0 $98.42 $13M −134,000 −$13M
JAZZ, Jazz Pharmaceuticals 1.89% Exit 0 $124.15 $9.9M −80,000 −$9.9M
NBIX, Neurocrine Biosciences 1.81% Exit 0 $110.60 $9.5M −85,700 −$9.5M
XBI, SPDR Ser Trust 1.45% Exit 0 $81.10 $7.6M −94,000 −$7.6M
CNTA, Centessa Pharmaceuticals 1.45% Exit 0 $14.38 $7.6M −529,000 −$7.6M
AVTR, Avantor 1.40% Exit 0 $16.21 $7.3M −453,000 −$7.3M
IDYA, Ideaya Biosciences 1.39% Exit 0 $16.38 $7.3M −445,000 −$7.3M
Janux Therapeutics 1.33% Exit 0 $27.00 $7M −258,000 −$7M
Blueprint Medicines 1.16% Exit 0 $88.51 $6.1M −68,500 −$6.1M
UTHR, United Therapeutics 0.99% Exit 0 $308.27 $5.2M −16,800 −$5.2M
BRKR, Bruker 0.91% Exit 0 $41.74 $4.8M −115,000 −$4.8M
BHVN, Biohaven 0.66% Exit 0 $24.04 $3.5M −145,000 −$3.5M
ACAD, Acadia Pharmaceuticals 0.54% Exit 0 $16.61 $2.8M −169,000 −$2.8M
RPRX 0.52% Exit 0 $31.13 $2.7M −87,000 −$2.7M
CAPR 0.43% Exit 0 $9.49 $2.3M −239,000 −$2.3M
LXEO, Lexeo Therapeutics 0.43% Exit 0 $3.47 $2.2M −645,000 −$2.2M
Vera Therapeutics 0.42% Exit 0 $24.02 $2.2M −91,000 −$2.2M
Regenxbio 0.35% Exit 0 $7.15 $1.9M −260,000 −$1.9M
IONS, Ionis Pharmaceuticals 0.35% Exit 0 $30.17 $1.8M −60,000 −$1.8M
MIRM, Mirum Pharmaceuticals 0.34% Exit 0 $45.05 $1.8M −40,000 −$1.8M
NAMS 0.27% Exit 0 $20.47 $1.4M −68,000 −$1.4M
Agilon Health 0.25% Exit 0 $4.33 $1.3M −305,100 −$1.3M
PCVX, Vaxcyte 0.17% Exit 0 $37.74 $868K −23,000 −$868K
Hyperfine 0.03% Exit 0 $0.7157 $159K −222,174 −$159K

Weight bar: held both quarters added sold at this quarter’s reported price

* Reported price is value ÷ shares from the 13F as of period end, not a live market quote. Weight % is each long-equity position ÷ full 13F AUM, so rows may not sum to 100% when the filing includes options or other non-equity (excluded from this table). Share change and $ change are vs 2025 Q1. Click a column header to sort, or New, Hold, Add or Reduce to bring those moves to the top. Exit opens the last-held block below.

Filings history

20 periods, with AUM normalized

Newest 13Fs
Period Holds AUM QoQ Form Filed Filing ID
2026 Q2 45 $624M +41.2% 13F-HR 8/14/2026 000179182726000005
2026 Q1 45 $494M — new holds 5/28/2026 000179182726000004
2026 Q1 46 $442M +27.4% 13F-HR 5/13/2026 000179182726000003
2025 Q4 39 $347M −21.0% 13F-HR 2/13/2026 000179182726000002
2025 Q3 43 $439M −12.5% 13F-HR 11/14/2025 000179182725000008
2025 Q2 56 $502M −4.4% 13F-HR 8/14/2025 000179182725000007
2025 Q1 67 $525M −48.4% 13F-HR 5/15/2025 000179182725000005
2024 Q4 63 $1B −48.1% 13F-HR 2/14/2025 000179182725000002
2024 Q3 81 $2B −16.7% 13F-HR 11/14/2024 000179182724000011
2024 Q2 85 $2.4B −24.1% 13F-HR 8/14/2024 000179182724000007
2024 Q1 90 $3.1B +13.0% 13F-HR 5/15/2024 000179182724000004
2023 Q4 74 $2.7B +10.5% 13F-HR 2/14/2024 000179182724000002
2023 Q3 83 $2.5B −13.3% 13F-HR 11/14/2023 000179182723000006
2023 Q2 93 $2.9B −5.0% 13F-HR 8/14/2023 000179182723000004
2023 Q1 83 $3B −34.7% 13F-HR 5/15/2023 000179182723000003
2022 Q4 85 $4.6B −6.2% 13F-HR 2/14/2023 000179182723000002
2022 Q3 97 $4.9B +12.9% 13F-HR 11/14/2022 000179182722000008
2022 Q2 82 $4.4B −9.3% 13F-HR 8/15/2022 000179182722000006
2022 Q1 92 $4.8B +1.9% 13F-HR 5/16/2022 000179182722000004
2021 Q4 97 $4.7B +4.5% 13F-HR 2/14/2022 000179182722000002
2021 Q3 105 $4.5B — 13F-HR 11/15/2021 000179182721000006

About

Avidity Partners Management LP

21 processed 13Fs on this site, 2021 Q3 to 2026 Q2

Entity
Avidity Partners Management LP
Notable person
David Witzke
Location
Dallas, TX
All SEC filings
View on sec.gov

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

  • The Essays of Warren Buffett, 8th Ed., Warren Buffett, Lawrence A. Cunningham View on Amazon
  • One Up On Wall Street (Lynch), Peter Lynch View on Amazon

More on the shelf